Compare Novavax Inc (NVAX) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Sezzle Inc — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while Sezzle Inc trades at $118.51 (market cap $3.94B). The key difference: Sezzle Inc is far larger — about 2.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SEZL | |
|---|---|---|
Market Cap | $1.62B | $3.94B |
Sector | Health | Technology |
52-Week High | $11.19 | $188.55 |
52-Week Low | $6.22 | $50.97 |
Enterprise Value | $1.20B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
SEZL trades at $118.35, down 1.85% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 30.35% net income margin and consistent earnings beats in recent quarters. Recent business developments include merchant network expansion with Gymshark and Debenhams Group, while analyst consensus remains bullish with a $161.17 price target representing 36% upside potential.
SEZL presents a compelling growth story with robust profitability metrics and expanding market presence, though technical weakness and high valuation multiples warrant caution. The stock offers significant upside based on analyst targets but faces execution risks in competitive fintech landscape and potential market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
